个人简介

Dr. Kieren Marr is the medical director of the Transplant and Oncology Infectious Diseases Program and a professor of medicine and oncology at the Johns Hopkins University School of Medicine. Dr. Marr, a member of the Johns Hopkins Kimmel Cancer Center, trained at Hahnemann University, Duke University and the University of Washington / Fred Hutchinson Cancer Research Center, where she was on faculty for 13 years prior to relocation to Johns Hopkins in 2008. Dr. Marr is a member of several national and international professional organizations, numerous national scientific steering committees, has authored over 150 peer-reviewed publications and textbook chapters, and edited two books in the area of infectious diseases involving immunosuppressed hosts. She is an elected member of the American Society for Clinical Investigators (ASCI) and is known worldwide for her translational and clinical research focused on diagnostics and treatment of invasive fungal infections. Her research has led to establishment of a JHU start-up company, MycoMed Technologies, focused on development of devices and drugs to enable strategies to prevent fungal infections in medically immunosuppressed people. She has an active academic interest in medical research innovation and commercialization and holds a co-appointment in the Carey School of Business. Dr. Marr sees patients and is active in clinical teaching as part of the Barker Firm faculty in the Department of Medicine, and the Transplant and Oncology Infectious Diseases inpatient and outpatient teams. MD, Hahnemann University School of Medicine (1993)

研究领域

Prevention and treatment of infections in medically immunosuppressed patients; Diagnosis and management of invasive

Antimicrobial development and clinical trials Diagnosis and management of invasive fungal infections Prevention and treatment of infections in medically immunosuppressed patients

近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Marr, K.A. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol. 2009 Dec 16. Marr, K.A.; Bow, E.; Chiller, T.; Maschmeyer, G.; Ribaud, P.; Segal, B.; Steinbach, W.; Wingard, J.R.; Nucci, M. Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009 Oct;44(8):483-487. Neofytos, D.; Horn, D.; Anaissie, E.; Steinbach, W.; Olyaei, A.; Fishman, J.; Pfaller, M.; Chang, C.; Webster, K.; Marr, K. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009 Feb 1;48(3):265-273. Staab, J.F.; Balajee, S.A.; Marr, K.A. Aspergillus section Fumigati typing by PCR-restriction fragment polymorphism. J Clin Microbiol. 2009 Jul;47(7):2079-2083. Chaudhary, N.; Staab, J.F.; Marr, K.A. Healthy human T-Cell Responses to Aspergillus fumigatus antigens. PLoS One. 2010;5(2):e9036. Marr, K.A. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol. 2010 Mar;22(2):138-142. Marr, K.A.; Subramanian, A.K. Transplantation represents one of the true modern advances in medicine, presenting new and effective treatments for organ and bone marrow failure and neoplastic disorders. Preface. Infect Dis Clin North Am. 2010 Jun;24(2):xiii-v. Staab, J.F.; Kahn, J.N.; Marr, K.A. Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent. Antimicrob Agents Chemother. 2010 Dec;54(12):4992-4998. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers MED, Corey L, Boeckh M. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo controlled trial. Blood. 2000; 96 (6):2055. Marr KA, Lyons CN, Ha K, Rustad TR, White TC. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother. 2001. 46(1): 52. Marr KA, Carter R, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients Clin Infect Dis. 2002; 34:909-17. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern W, Marr KA, Ribaud P, Lortholary O, Sylvester R, de Pauw B. Randomized comparison of voriconazole and amphotericin B in primary therpay of invasive aspergillosis. A collaborative study of the EORTC invasive fungal infection group and the global aspergillosis study group. New Engl J Med. 2002; 347:408-15. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risks. Blood. 2002; 10(13):4358-66. Fukuda T, Boeckh M, Carter R, Sandmaier B, Maris M, Maloney D, Martin P, Storb R, Marr KA. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation after nonmyeloablative conditioning: risks and outcomes. Blood. 2003; 102:827-33. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee A, Musher B, Corey L. Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic HSCT patients. Blood. 2004; 103: 1527-33. Marr KA, Balajee SA, Leisenring W, Weaver B, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of aspergillosis: Variables that affect performance. J Infect Dis. 2004; 190:641-9. Musher B, Fredricks D, Leisenring W, Balajee SA, Marr KA. Aspergillus galactomannan EIA and quantitative PCR for diagnosis of aspergillosis in HCT patients using bronchoalveolar lavage. J Clin Microbiol. 2004; 42(12): 5517-22. Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov: a new sibling species of A. fumigatus. Eukaryotic Cell. 2005; 4: 625-632. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Platelia Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005; 40(12):1762-9. Gersuk GM, Underhill DM, Zhu L, Marr KA. Dectin-1 and Toll-like receptors permit macrophages to distinguish between different Aspergillus fumigatus cellular states. J Immunology. 2006; 176:3717-24. Balajee SA, Nickle D, Varga J, Marr KA. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping . Euk Cell. 2006; 5:1705-1712. Upton A, Kirby K, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007; 44(4): 531-40. Upton A, Fraser JA, Kidd SE, Bretz C, Bartlett KH, Heitman J, Marr KA. First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence of spread of the Vancouver Island outbreak. J Clin Microbiol. 2007; 45(9): 3086-8. Bretz C, Gersuk G, Knoblaugh S, Chaudhary N, Randolph-Habecker J, Hackman R, Staab J, Marr KA. MyD88-signaling contributes to early pulmonary responses to Aspergillus fumigatus. Infect Immun. 2008; 76(3): 952-8. Zaas AK, Liao G, Chien JW, Weinberg C, Shore D, Giles SS, Marr KA, Usuka J, Burch L, Perera L, Perfect JR, Peltz G, Schwartz DA. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLos Genetics 2008 4(6):e1000101.